An investigator-initiated clinical study of GPN02006 developed by Grand Pharmaceutical Group (HKG:0512) in cooperation with two other parties for the diagnosis of hepatocellular carcinoma recently achieved a milestone breakthrough, a Tuesday Hong Kong bourse filing said.
The clinical results showed the drug exhibits "excellent" safety and imaging efficacy, as well as high-quality imaging 30 minutes post administration.
The drug was developed in cooperation with Wuhan Ruidifu Biotechnology and JECHO Biopharmaceuticals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。